Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Other Income and Expenses [Abstract]
Interest income		$ (177)	$ (14)
Interest expense		318	322
Net interest expense		141	308
Royalty-related income		(204)	(173)
Net (gains)/losses on asset disposals		(7)	(1)
Net (gains)/losses recognized during the period on equity securities	[1],[2]	451	699
Income from collaborations, out-licensing arrangements and sales of compound/product rights		(68)	(9)
Net periodic benefit costs/(credits) other than service costs		(80)	(283)
Certain legal matters, net	[3]	36	79
Certain asset impairments	[4]	264	0
Haleon/Consumer Healthcare JV equity method (income)/loss	[5]	(68)	(184)
Other, net	[6]	(396)	(88)
Other (income)/deductions––net		$ 70	$ 350

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The losses in the first quarter of 2023 include, among other things, unrealized losses of $363 million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech. The losses in the first quarter of 2022 included, among other things, unrealized losses of $473 million related to our investment in BioNTech.

[3] The first quarter of 2023 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The first quarter of 2022 includes certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.

[4] The first quarter of 2023 primarily represents intangible asset impairment charges, including $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflects unfavorable pivotal trial results and updated commercial forecasts, and $120 million associated with our Biopharma segment due to the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer, acquired in our Array BioPharma Inc. acquisition.

[5] See Note 2C.

[6] The first quarter of 2023 primarily includes, among other things, dividend income of $211 million from our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $92 million from our investment in ViiV.